Search company, investor...

Mind-NRG

mind-nrg.com

Stage

Series B | Dead

Total Raised

$10M

Last Raised

$8M

About Mind-NRG

Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 is being developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia.

Headquarters Location

Rue de Jargonnant 2

Geneva, CH-1207,

Switzerland

+41 22 737 00 00

Loading...

Loading...

Mind-NRG Patents

Mind-NRG has filed 7 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • neurological disorders
  • proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/23/2019

10/27/2020

Method of effecting neuroprotection using soluble neuregulin isoforms

Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins

Grant

Application Date

5/23/2019

Grant Date

10/27/2020

Title

Method of effecting neuroprotection using soluble neuregulin isoforms

Related Topics

Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins

Status

Grant

Latest Mind-NRG News

Mind-NRG Closes €6M Series B Financing

Sep 4, 2013

By FinSMEs Mind-NRG , a Geneva, Switzerland-based company focusing on developing neuregulins to treat neurodegenerative diseases, closed its €6m (approximately $8m) Series B financing. Backers included new investor LRM and existing investor Index Ventures . Following the investment, Debora Dumont, Head of Health & Care at LRM will join the company’s board of directors. Created in 2010, Mind-NRG is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. In particular, it is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia. The company plans to use the funding to continue to develop NRG-101’s neuroprotective effect in Parkinson’s disease, with the aim of advancing the compound to proof-of-concept studies in patients. FinSMEs

Mind-NRG Frequently Asked Questions (FAQ)

  • Where is Mind-NRG's headquarters?

    Mind-NRG's headquarters is located at Rue de Jargonnant 2, Geneva.

  • What is Mind-NRG's latest funding round?

    Mind-NRG's latest funding round is Series B.

  • How much did Mind-NRG raise?

    Mind-NRG raised a total of $10M.

  • Who are the investors of Mind-NRG?

    Investors of Mind-NRG include Index Ventures and LRM Capital.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.